untitled design

Covid-19: Brazil registers 389 deaths and more than 13 thousand cases in 24 hours

Brazil registered 389 deaths and 13,321 cases of Covid-19 in the last 24 hours. This Friday (5), the moving averages of deaths and infections were 228 and 9,865, respectively.

Data are from the National Council of Health Secretaries (Conass). With the update, the country has a total of 609,060 deaths and 21,862,458 confirmed infections since the beginning of the pandemic in March 2020.

Pfizer Antiviral Against Covid-19

Drugmaker Pfizer said on Friday that its experimental antiviral coronavirus pill reduced the risk of hospitalization and death in high-risk patients who participated in the study. The chances of severe cases were reduced by 89% with the drug. Read more.

US President Joe Biden said the United States has guaranteed millions of doses of the pill in case the drug becomes an effective treatment for the disease. Read more.

Pharmaceutical company Pfizer is in talks with 90 countries on contracts to supply the experimental pill. Read more.

Pfizer Vaccine for Children

Pfizer must request the definitive registration of the vaccine against Covid-19 for children from 5 to 11 years of age at the National Health Surveillance Agency (Anvisa) by next Friday (12). Read more.

delay in the second dose

Until October 25, more than 14 million people had their second dose of vaccine against Covid-19 in Brazil delayed by at least 15 days. The number is double that observed on September 15, when 7 million were registered, according to the second edition of the Bulletin VigiVac of the Oswaldo Cruz Foundation (Fiocruz) of Bahia. Read more.

Covid-19 in Europe

Europe is facing a potentially devastating winter, which could lead half a million people to die from Covid-19, warned the World Health Organization (WHO) on Thursday (4), when it issued a warning about an increase in cases and lamented the failures of vaccination in certain areas of the continent. Read more.

Reference: CNN Brasil

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular